ライフサイエンスコーパス: treatment for

1 r discontinue CPT (placebo, n = 86) as daily treatment for 1 year.

2 During each period, animals were kept on treatment for 10 day, with sample collection on the fina

3 encing clozapine and again after 6 months of treatment for 33 patients with treatment-resistant schiz

4 CL treatment for 7 days increased SAT adipocyte beiging and

5 esting may inform prevention, diagnosis, and treatment for a broad range of CF carrier-related condit

6 HTx appears to be an effective treatment for a select group of muscular dystrophy patie

7 chnologies have rapidly developed to provide treatment for a substantial number of patients with seve

8 n in controlled studies, dissipate following treatment for about half of all couples, and may be expl

9 o unequivocal recommendation of an effective treatment for aceruloplasminaemia.

10 semiannual treatment was superior to annual treatment for achieving sustained clearance of Onchocerc

11 her research is needed to identify effective treatments for acute heart failure in older patients.

12 tigating the safety and efficacy of systemic treatments for AD up to February 2020.

13 had completed at least one previous line of treatment for advanced breast cancer or relapsed within

14 most common cancers worldwide, however, the treatment for advanced HCC remains unsatisfactory.

15 ivation therapy (ADT) is still a mainstay of treatment for advanced prostate cancer.

16 s from the Advancing Cryptococcal Meningitis Treatment for Africa trial were followed for 12 months.

17 will be of importance for the development of treatments for age-related hearing disorders.

18 The study illustrates how combinatorial treatments for aggressive, T cell-deficient cancers can

19 There is no effective treatment for AKI and new therapies are urgently needed.

20 binge drinking in female mice suggests that treatments for alcohol use disorder in women may need to

21 Mean time to treatment for all patients was 27.8 +/- 41.4 days.

22 argeting GRPR and NPRA may provide effective treatments for allergic contact dermatitis-associated ch

23 The lack of effective treatments for Alzheimer's disease (AD) is alarming, con

24 lternative target and strategy to antibiotic treatment for animal growth promotion.

25 However, neurons with continued ACV treatment for another 4 days showed a gradual recovery o

26 The gold standard treatment for anterior cruciate ligament (ACL) reconstru

27 rs, could potentially serve as complementary treatment for anti-NMDAR encephalitis and deserve future

28 tic valve replacement (SAVR) represent the 2 treatments for aortic bioprosthesis failure.

29 s might provide new platforms for developing treatments for AS and various forms of autism.

30 ttransplant should not undergo screening and treatment for asymptomatic bacteriuria.

31 All patients had been off treatment for at least 24 months at data collection.

32 f age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who

33 A total of 686 patients undergoing treatment for AUD between 2013 and 2017 were eligible (7

34 A fundamental challenge in developing treatments for autism spectrum disorders is the heteroge

35 y, surgical resection is also the definitive treatment for biliary tract cancers, and liver transplan

36 deprivation therapy (IADT) is an attractive treatment for biochemically recurrent prostate cancer (P

37 ew recent advances toward the goal of better treatments for bipolar disorder, and we outline major ch

38 Unfortunately, effective pharmacological treatments for bipolar disorders are not universally ava

39 ndent signaling is a cornerstone of adjuvant treatment for breast cancer, 25% of patients experience

40 Because treatments for breast cancer patients are largely design

41 hether PLK4 inhibitors can be leveraged as a treatment for cancer is not yet clear.

42 open new avenues for the prevention and the treatment for cardiovascular diseases (CVDs).

43 al participants receiving antibacterial drug treatment for CDI.

44 ranslating metabolomic data to develop novel treatments for Chagas disease.

45 y, the only approved hepatitis C virus (HCV) treatment for children aged <12 years is pegylated inter

46 disc areas) without evidence of or previous treatment for choroidal neovascularization in either eye

47 Interest in and access to surgical treatment for chronic lymphedema (LE) in the United Stat

48 have restricted our ability to develop novel treatments for clotting diseases.

49 Having treatment for CLTI or DFI in P2 was an independent predi

50 Convalescent plasma therapy is a leading treatment for conferring temporary immunity to COVID-19-

51 gh nasolacrimal duct probing is the standard treatment for congenital nasolacrimal duct obstruction (

52 ide important insights into the etiology and treatments for congenital heart disease.

53 ult in the development of alternative, novel treatments for corneal dystrophies, which may substantia

54 Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but t

55 35 studies that evaluated high-dose vitamin treatment for COVID-19, 27 (77%) excluded pregnant women

56 ising lead compound to develop new antiviral treatment for COVID-19.

57 arrant further development as an intravenous treatment for COVID-19.

58 Current treatments for COVID-19 are limited to supportive therap

59 als have been launched to identify effective treatments for COVID-19.

60 undermine efforts to develop evidence-based treatments for COVID-19.

61 including all patients > 18 years receiving treatment for culture-confirmed, drug-sensitive TB from

62 Treatment for DBA is associated with significant morbidi

63 measure in clinical trials investigating new treatments for degenerative retinal diseases.

64 ass index, the respective pre-surgery score, treatment for depression (time-varying) and pre-to-post-

65 of psychological interventions as first-line treatment for depression in low-income and middle-income

66 nt depression (ie, depression history but no treatment for depression within the past 2 years).

67 Despite the availability of effective treatments for depression, patients with co-occurring su

68 ms of resilience, and the development of new treatments for depression.

69 in vivo and may facilitate the discovery of treatments for diabetes.

70 cell growth and survival represent potential treatments for diabetes.

71 oagulation and antiviral agents are standard treatments for DIC but are gravely insufficient for any

72 tion of FKBP51 has emerged as possible novel treatment for diseases like major depressive disorder, o

73 There is an unmet need for treatments for diseases associated with aging.

74 Current treatments for diseases associated with GBM involvement

75 ransport pathways may lead to more effective treatments for diseases within the reproductive tract.

76 Treatments for diverticular disease include dietary fibr

77 of receiving the different possible initial treatments for DME (anti-vascular endothelial growth fac

78 Binding-competition during HD is a potential treatment for drug toxicities for which current recommen

79 tment for IDU-associated HIV infections with treatment for drug use disorders.

80 each participant at diagnosis and throughout treatment for drug-susceptible TB.

81 yme A (HMG-CoA) reductase inhibitor (statin) treatment for dyslipidemia, and group 2, those with newl

82 magnetic stimulation (rTMS) can be used as a treatment for dysphagia, its efficacy varies across indi

83 city on anti-VEGF efficacy to ensure optimal treatment for each individual.

84 patients and may explore further the cost of treatment for each treatment method.

85 rubicin plus cyclophosphamide as neoadjuvant treatment for early-stage TNBC.

86 hibitors (TKIs) plus MET TKIs are a possible treatment for EGFR mutation-positive lung cancers with M

87 n the development of preventive measures and treatments for end-stage liver disease in elderly patien

88 A 4-fold increase in the likelihood of treatment for endophthalmitis was observed with increasi

89 at has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis.

90 ence toward microbiome-targeted personalized treatments for FGIDs.

91 ergies, up until the end of January 2020, no treatment for food allergies had been approved by the US

92 No treatment for frontotemporal dementia (FTD), the second

93 4 pathway in glaucoma and provide a possible treatment for glaucoma by targeting this pathway.

94 ucoma, but only 2.6% had used marijuana as a treatment for glaucoma.

95 Treatment for glioblastoma (GBM) includes surgical resec

96 Evaluations of potential new treatments for gonorrhea currently make limited use of n

97 Colchicine, a commonly used treatment for gout, has recently emerged as a novel ther

98 in all patients who received the combination treatment for group A and progression-free survival in t

99 ations to seek new, personalized, and timely treatments for Group 2 PH.

100 dyspeptic patients, who did not receive any treatment for H. pylori.

101 Y90 is an effective treatment for HCC in the setting of bridging/downstaging

102 sublingual HDM tablet is an effective, safe treatment for HDM-induced allergic rhinitis.

103 on therapy has been approved as a first-line treatment for head and neck squamous cell carcinoma (HNS

104 ients receiving Interferon-alpha (IFN-alpha) treatment for Hepatitis-C develop major depressive disor

105 There are now effective treatments for hepatitis B and hepatitis C, and follow-u

106 gesting its high potential as an alternative treatment for herpetic diseases.

107 argely unsuccessful in identifying effective treatments for HFpEF but evidence supports the use of di

108 Unlike HFrEF, there are no effective treatments for HFpEF, which accounts for ~50% of heart f

109 Patients received standard treatment for HFrEF.

110 tion, genomic classification enables earlier treatment for high-risk patients as well as reduction of

111 hloroquine and azithromycin as an outpatient treatment for high-risk patients with coronavirus 19 sho

112 immunotherapies are at the forefront of new treatments for HIV infections.

113 There is no approved treatment for HMPV and only one prophylactic treatment a

114 clinical use of pegylated IFN-lambda1a as a treatment for human COVID-19(6).

115 e viewed as a reason to avoid or de-escalate treatment for hypertension.

116 Resistant starches may represent a novel treatment for IBD.

117 te pathways for prophylactic and therapeutic treatments for IBDs.

118 Guidelines advocate SET before invasive treatment for IC, but early revascularization remains wi

119 gram (RWHAP) is well positioned to integrate treatment for IDU-associated HIV infections with treatme

120 Propranolol is an approved treatment for IHs, but its mechanism of action remains u

121 that could lead to the identification of new treatments for improving patients' quality of life.

122 development of islatravir as a flexible-dose treatment for individuals with HIV-1 infection.

123 associated infections and providing the best treatment for infected individuals.

124 lying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infecti

125 intestinal microbiota has been proposed as a treatment for inflammatory bowel diseases (IBDs), but th

126 and escape mutants have been reported to all treatments for influenza A.

127 ase 1b of clinical trials, to be a potential treatment for IPF.

128 Treatments for IPF are limited to anti-inflammatory and

129 Many treatments for irritable bowel syndrome are available to

130 iological drivers may lead to novel targeted treatments for keloids.

131 Data to inform surveillance and treatment for leukaemia predisposition syndromes are sca

132 Treatment for LTBI was highly effective in preventing TB

133 (3HP) is currently recommended by the CDC as treatment for LTBI, experimental evidence for 3HP-mediat

134 l novel strategies for targeting HDAC10 as a treatment for lung cancer.

135 ymptoms for >= 6 months following antibiotic treatment for Lyme disease.

136 ti-vascular endothelial growth factor (VEGF) treatment for macular neovascularization (MNV).

137 identifying a favorable response for a drug treatment for major depressive disorder.

138 Thus, more effective treatments for major depression are needed, and targetin

139 While numerous treatments for major depression exist, many patients do

140 rapy unavailable to many patients undergoing treatment for malignancy, which would also be infeasible

141 Surgical excision is one of the main treatments for malignant tumors.

142 A mainstay treatment for many cancers is chemotherapy, for which th

143 hough local therapies remain the mainstay of treatment for many patients with brain metastases, a gro

144 urposing periods have led to advances in the treatment for many RAIDs.

145 H-1 and SF-1 modulators are highly sought as treatments for metabolic and neoplastic diseases, and RJ

146 ptide (CGRP) pathway inhibitors are emerging treatments for migraine.

147 's potential to be investigated further as a treatment for mild-to-moderate PUs infected with S. aure

148 s that matter to patients who are undergoing treatment for moderate to severe glaucoma, many of which

149 UBR5 is a potential therapeutic target in OC treatment for modulating the TME and cancer stemness.

150 Transplantation is the optimal treatment for most patients with end-stage kidney diseas

151 Despite decades of research, effective treatments for most cancers remain elusive.

152 the marrow, whereas BMAT was restored after treatment for multiple myeloma.

153 a anti-CD20 antibodies is a highly effective treatment for multiple sclerosis (MS).

154 y of NALCN and a foundation for discovery of treatments for NALCN channelopathies and other electrica

155 alternative treatment to lifelong anti-VEGF treatment for nAMD.

156 rldwide, and VEGF inhibitors are the primary treatment for nAMD.

157 Previous treatments for neonatal ROP included peripheral laser ab

158 potentially less toxic, more tumor-specific treatment for neuroblastoma than conventional cytotoxic

159 ly, there is a huge unmet need for effective treatments for neurodegenerative diseases.

160 Oxytocin may have promise as a treatment for neuropsychiatric disorders.

161 ynthetic tetrahydrocannabinol analogue, as a treatment for non-motor symptoms (NMS) in Parkinson's di

162 Pharmacological treatments for non-alcoholic steatohepatitis (NASH) are

163 novel therapeutic strategies for efficacious treatment for NSCLC.

164 alternative to other mechanical and thermal treatments for NVUGIB, particularly for ulcers in diffic

165 This Review discusses the core priority treatments for OA, including exercise and physical activ

166 Improved treatment for onchocerciasis is needed to accelerate onc

167 significantly (p<0.05) following successful treatment for onchocerciasis.

168 considered as relapse prevention maintenance treatment for opioid addiction.

169 monkeys, suggesting it could be an effective treatment for opioid use disorder (OUD).

170 assessed the number of individuals receiving treatment for opioid use disorder in the United States b

171 Treatments for OUD may be limited by poor adherence to t

172 pports its further clinical development as a treatment for P. vivax malaria.

173 that will help in developing more effective treatments for pain and addiction.

174 es fear, and mGluR2 PAMs could be a targeted treatment for panic symptoms in PD and PTSD patients.

175 as the cornerstone to delivering successful treatment for patients suffering from primary hyperparat

176 ve been increasingly used as a first-line of treatment for patients undergoing oncologic surgeries.

177 h power assisted liposuction is an effective treatment for patients with chronic extremity lymphedema

178 PCSL with Dex might be a potential treatment for patients with chronic intractable insomnia

179 ide rationale for the assessment of KEs as a treatment for patients with heart failure.

180 Anti-IL-5 therapy is a potential treatment for patients with hypereosinophilic syndrome (

181 PARP inhibition is an effective treatment for patients with MBC and gPALB2 or sBRCA1/2 m

182 surgery is well established as an effective treatment for patients with obesity and type 2 diabetes

183 stigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wi

184 w considered standard of care as second-line treatment for patients with recurrent/refractory pericar

185 The addition of IC to treatment for patients with SR-average disease did not i

186 first RCT to compare medical versus surgical treatments for patients presenting with advanced open an

187 Effective treatments for patients with cholangiocarcinoma after pr

188 exposure has raised a growing need for novel treatments for patients with relapsed or refractory mult

189 this condition is critical to developing new treatments for patients.

190 ability may provide a key for developing new treatments for PD.

191 unotherapy (EPIT) may be a relevant and safe treatment for peanut allergy and may improve the quality

192 These results demonstrate that daily EPIT treatment for peanut allergy beyond 1 year leads to cont

193 Domain-specific cognitive training treatments for pediatric anxiety disorders rely on accur

194 amine maintenance therapy shows promise as a treatment for people with cocaine addiction.

195 amide as a safe, well tolerated, and durable treatment for people with HIV, with no emergent resistan

196 gnosis of peri-implant status after surgical treatment for peri-implantitis.

197 Shorter courses of antibiotic treatment for PNA, UTI, and ABSSSI with bacteremia were

198 Currently, an effective therapeutic treatment for porcine reproductive and respiratory syndr

199 Pericardiectomy is a safe and effective treatment for posttransplant constrictive pericarditis.

200 exact cause of HLH is crucial, as definitive treatment for primary disease is hematopoietic stem cell

201 ric antigen receptor T cells as an effective treatment for primary, metastatic and recurrent group 3

202 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who

203 arinoids, have previously been proposed as a treatment for PrP prion disorders.

204 ion enhancer represents an effective topical treatment for psoriasis.

205 gic, and 10% were not receiving any systemic treatment for psoriasis.

206 rt phase 3 investigation of bimekizumab as a treatment for psoriatic arthritis.

207 attention may guide the development of novel treatments for psychiatric disorders with attention defi

208 ontrols was less responsive to psychotherapy treatment for PTSD and failed to respond to an antidepre

209 sis of multiple regions of a tumor alongside treatment for quantitative modeling and prediction of ou

210 Taken together, our findings suggest that treatments for RABV must consider the balance between th

211 atonin are most commonly used as symptomatic treatments for RBD, clinical trials of symptomatic treat

212 l cells (MSCs) to provide a more generalized treatment for RDEB.

213 rafts are considered to be the gold standard treatment for reconstruction of large bone defects resul

214 nd costs of rehospitalization and/or further treatments for recurrent CDI.

215 underlining the importance of successful HCV treatment for reducing ESLD.

216 Fingolimod is an effective treatment for relapsing-remitting multiple sclerosis.

217 ion from experts supports the application of treatments for related conditions, such as Parkinson's d

218 s the efficiency of a subsequent AAV9/CRISPR treatment for repression of proprotein convertase subtil

219 Allergen immunotherapy is a proven, safe treatment for respiratory allergies.

220 mation for health assessment, diagnosis, and treatment for respiratory diseases such as asthma, chron

221 from autonomic nerves will help develop new treatments for restoring regulatory functions.

222 were randomized in the Study of Comparative Treatments for Retinal Vein Occlusion 2, and 88 particip

223 d in 130/458 (28.4%) vs 126/485 (26.0%); and treatment for retinopathy of prematurity was required in

224 should not be considered as standard of care treatment for retroperitoneal sarcoma.

225 Current understanding and treatment for reversing of the fibrotic process is limit

226 ly established cold temperature conditioning treatments for ripening of two pear cultivars, 'D'Anjou'

227 and SGA status, worst stage of and need for treatment for ROP, and postnatal growth was obtained.

228 Combined treatment for SAM and MAM is non-inferior to standard ca

229 There are currently few approved effective treatments for SARS-CoV-2, the virus responsible for the

230 The mainstay of early treatment for SCI for all cases was blood pressure contr

231 ey suggest using (223)RaCl(2) as an adjuvant treatment for select patients at early stages of breast

232 al approach with the possibility of top-down treatment for selected patients.

233 spite extensive investigations, an effective treatment for sepsis remains elusive and a better unders

234 and considerably higher than use of systemic treatments for serious manifestations of the disease and

235 Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but there is unc

236 Oral corticosteroid (OCS) treatment for severe asthma is associated with substanti

237 apeutic interventions constitute a promising treatment for severe COVID-19 patients.

238 ctroconvulsive therapy (ECT) is an effective treatment for severe medication-resistant depression.

239 Phototherapy is a standard treatment for severe neonatal jaundice to remove toxic b

240 Bariatric surgery is an effective treatment for severe obesity.

241 lative efficacy of biologics in reducing OCS treatment for severe, uncontrolled asthma is not fully c

242 ore efficacious than using only one of these treatments for skin flap survival.

243 rathecal microRNA can be used as a potential treatment for SOD1-mediated ALS.

244 herapeutic drug, which is used as first-line treatment for some types of colorectal carcinoma, causes

245 aclofen is a GABA(B) agonist prescribed as a treatment for spasticity in stroke, brain injury and mul

246 refore, we recommend observation rather than treatment for stable dysplastic hips.

247 Current treatments for strabismus involve ocular alignment throu

248 Our work may lead to improved diagnosis and treatment for stress disorders such as PTSD, that result

249 esponse and that FAAH inhibition may aid the treatment for stress-related psychiatric disorders, such

250 resilience could be targeted to develop new treatments for stress-related disorders like depression.

251 rograms such as needle and syringe programs, treatment for substance use disorder, and HIV and HCV tr

252 nfacine has been investigated as a potential treatment for substance use disorders.

253 targeting stressors and stress allostasis in treatments for SUDs.

254 The effect of surgical treatment for supratentorial spontaneous intracerebral h

255 Catheter ablation is an increasingly used treatment for symptomatic atrial fibrillation (AF).

256 Among patients receiving initial treatment for symptomatic, paroxysmal atrial fibrillatio

257 udy population for testing disease-modifying treatments for synucleinopathies, since RBD represents a

258 Islet transplantation is a promising treatment for T1D, but long-term graft viability and fun

259 aluate outcomes of older patients undergoing treatment for TB disease, including the frequency of adv

260 Because current treatments for TBI merely ameliorate secondary effects o

261 at empagliflozin warrants further study as a treatment for the disorder.

262 hat the benefits and costs of FGD wastewater treatment for the median plant will poorly describe the

263 nses to at least one adequate antidepressant treatment for the prevailing episode were assigned rando

264 ffective alternative to single screening and treatment for the prevention of the adverse effects of m

265 ventive treatment is a promising alternative treatment for the reduction of malaria in pregnancy.

266 gement of anticoagulation is the mainstay of treatment for the vast majority of patients.

267 lop effective vaccines, identify efficacious treatments for the infection and its complications, and

268 les to help select the right suicide-focused treatments for the right patients at the right times.

269 venom variation and deliver next-generation treatments for the world's most lethal neglected tropica

270 Patients who received treatment for their H pylori infection still had an incr

271 F-1alpha blockade could be a novel avenue of treatment for these tumors.

272 essential to provide and coordinate the best treatments for these patients.

273 nsplantation (HCT) remains the only curative treatment for this condition, but transplant survival in

274 l highlight the benefits of disease-specific treatment for this condition.

275 d pharmacotherapy remains the cornerstone of treatment for this condition; improved understanding of

276 ng that JNK inhibition represents a possible treatment for this disease.

277 ossible strategies for exploiting the UPR as treatment for this disease.

278 andidates to facilitate the development of a treatment for this disorder and similar diseases.

279 future studies for the development of novel treatments for this disease.

280 endation regarding the use of extracorporeal treatments for this drug.

281 ccurate evidence regarding effective medical treatments for this infection.

282 Multikinase inhibitors are effective treatments for thyroid cancers, acting primarily as anti

283 As a consequence, treatments for tinnitus may need to enhance the cortical

284 rom studies published to date on a preferred treatment for TON.

285 al intermediate nucleus of the thalamus is a treatment for tremor disorders.

286 ere is a clinically unmet need for effective treatments for triple-negative breast cancer (TNBC), as

287 and chest radiography) to determine whether treatment for tuberculosis should be started or to recei

288 Metformin is the first line of treatment for type 2 diabetes, and one of the underlying

289 dequately controlled despite optimal medical treatment for type 2 diabetes.

290 efficacious and generally safe as adjunctive treatment for uncontrolled PGTCS in patients with IGE.

291 10, 20, and 30 years led to 978 prophylactic treatments for unruptured aneurysms, 19 procedure-relate

292 the effectiveness of steam (>=100 degrees C) treatments for up to 120 secs.

293 e use of gamma knife radiosurgery as primary treatment for uveal melanoma or uveal metastases.

294 nabis and other exocannabinoids as anecdotal treatments for various GI disorders inspired the search

295 nticoagulants (DOACs) have become first-line treatment for venous thrombotic events.

296 information for the development of improved treatments for vital pulp therapy and dentin regeneratio

297 There is no approved treatment for vitiligo repigmentation and current off-la

298 Bariatric surgery is the most effective treatment for weight loss.

299 estigation of potential consequences of this treatment for youth experiencing gender dysphoria.

300 ts that may improve early identification and treatment for youth with STBs and NSSI.